Pinnacle Spine Group Announces Issuance Of US Patent Relating To The InFill® Graft Delivery System

Pinnacle Spine Group's InFill® Graft Delivery System has been issued a US Patent. The innovative Infill Graft Delivery system allows for precise post-implant placement of biologic material in a way that dramatically improves endplate-to-endplate biologic engagement.

Dallas, Texas (PRWEB) - Pinnacle Spine Group, LLC, (“Pinnacle”) a Dallas, Texas-based company that designs, develops, manufactures and markets spinal implants and instruments, announces the USPTO has issued US Patent 8,308,805, covering the InFill® Graft Delivery System. Pinnacle received FDA clearance for the system in September 2012, and now has received its first formal patent issuance.

The Infill Graft Delivery System allows precise placement of approved biologic material into an implanted cage. This enhanced “post-fill” method can dramatically improve endplate-to-endplate biologic engagement.

The InFill Graft Delivery System compliments Pinnacle’s InFill Direct Lateral System. Comprehensive instrumentation, including a unique retractor system, extensive disc and endplate preparation options, as well as other specialized instrumentations to address the more challenging fusion levels complete the system.

Visit us on the web at http://www.pinnaclespinegroup.com. To learn more about the InFill Graft Delivery System, visit http://www.pinnaclespinegroup.com/graft for more information, including a short demonstration video.

Pinnacle Spine Group was founded with the focused goal of developing innovative medical devices, conceived in the operating room, for surgical procedures of the spine. The objective for every device and instrument we develop is a better outcome for the patient, and a better experience for the surgeon and operating room staff.